Acute myeloid leukemia (AML) is a heterogenous disorder that results from a block in the
differentiation of hematopoietic progenitor cells along with uncontrolled proliferation. In …

To investigate the pathogenesis and the refractory/relapse mechanisms in patients with t
(16; 21)(p11; q22), we retrospectively analyzed the clinical data of six cases in our hospital …

Recurrent or residual leukemia found in extramedullary sites after intensive treatments
adversely affects prognosis. To summarize the sites and outcomes when extramedullary …

This study reports a 1-year-old boy with precursor B cell acute lymphoblastic leukemia (ALL)
carrying t (16; 21)(p11; q22). Reverse transcriptase-polymerase chain reaction (RT-PCR) …

Acute myelogenous leukemia (AML) is considered to be in complete remission when fewer
than 5% of the cells in bone marrow are blasts. Nevertheless, approximately two thirds of …

Reciprocal t (16; 21)(p11; q22) is a rare chromosomal abnormality in acute myeloid
leukemia (AML). The chimeric transcript FUS–ERG formed by this translocation which …

Relapse remains the main cause of treatment failure in acute myeloid leukaemia (AML).
Studies to date suggest that monitoring of minimal residual disease (MRD) in AML is useful …

Abstract Patients with t (16; 21) acute myelogenous leukemia (AML) who receive
chemotherapy have poor outcomes. The treatment efficacy of allogeneic hematopoietic stem …

We report the case of a 37‐year‐old woman who had a relapse of acute myeloid leukemia
(AML) during treatment for chronic graft versus host disease (cGVHD) after allogeneic bone …

t(16;21）（p11；q22）急性髓系白血病九例报告并文献复习- PMC Back to Top Skip to main content
NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main …